Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 11/20 | 0.61 |
| ▸ | CA9 | Q16790 | 11/20 | 0.61 |
| ▸ | CA1 | P00915 | 10/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 9/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 8/20 | 0.47 |
| ▸ | TNF | P01375 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | PRKCG | P05129 | 1/20 | 0.46 |
| ▸ | PRKCB | P05771 | 1/20 | 0.46 |
| ▸ | PRKCA | P17252 | 1/20 | 0.46 |
| ▸ | PRKACA | P17612 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | PRKACG | P22612 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30075444 | 0.86 | CA1 (0.61) | CA2CA9CA1MAPK1MEN1 | |
| SCHEMBL1551138 | 0.86 | CA1 (0.61) | CA2CA9CA1MAPK1MEN1 | |
| Hydrochloric Acid SCHEMBL29748700 | 0.84 | LMNA (0.61) | CA2CA9CA1MAPK1MEN1 | |
| Hydrochloric Acid SCHEMBL9483668 | 0.84 | LMNA (0.61) | CA2CA9CA1MAPK1MEN1 | |
| SCHEMBL31527752 | 0.84 | CA1 (0.59) | CA2CA9CA1MAPK1MEN1 | |
| SCHEMBL30002842 | 0.82 | TNF (0.46) | CA2CA9CA1MAPK1TNF | |
| SCHEMBL26422606 | 0.82 | TNF (0.46) | CA2CA9CA1MAPK1TNF | |
| SCHEMBL3129943 | 0.82 | TNF (0.46) | CA2CA9CA1MAPK1TNF | |
| SCHEMBL11983469 | 0.82 | TNF (0.46) | CA2CA9CA1MAPK1TNF | |
| Hydrochloric Acid SCHEMBL27788261 | 0.81 | TNF (0.45) | CA2CA9CA1MAPK1TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115232144-B | Nitrogen-containing condensed ring derivative, pharmaceutical composition, and preparation method and application thereof | 长春金赛药业有限责任公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-115232144-A | Nitrogen-containing fused ring derivative, pharmaceutical composition, preparation method and application thereof | 长春金赛药业有限责任公司 | 2022-10-25 | — | — | CN | disclosed |
| US-11072581-B2 | N-acyl-arylsulfonamide derivatives as aminoacyl-tRNA synthetase inhibitors | Oxford Drug Design Limited (GB) | 2021-07-27 | — | — | US | disclosed |
| CN-108350421-A | Method for preparing retinal pigment epithelial cells | 大日本住友制药株式会社 | 2018-07-31 | — | — | CN | disclosed |
| US-20180022696-A1 | NOVEL N-ACYL-ARYLSULFONAMIDE DERIVATIVES AS AMINOACYL-TRNA SYNTHETASE INHIBITORS | THE LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) | 2018-01-25 | — | — | US | disclosed |
| US-20180022696-A1 | NOVEL N-ACYL-ARYLSULFONAMIDE DERIVATIVES AS AMINOACYL-TRNA SYNTHETASE INHIBITORS | THE LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) | 2018-01-25 | — | — | US | disclosed |
| CN-104603118-B | Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators of the orphan nuclear receptor ROR γ | 菲尼克斯药品股份公司 | 2017-10-03 | — | — | CN | disclosed |
| CN-107007597-A | It is used as the thiazole of orphan nuclear receptor ROR γ instrumentalities through formamide or sulfonamide substitutions and the pharmaceutical applications of related derivatives | 菲尼克斯药品股份公司 | 2017-08-04 | — | — | CN | disclosed |
| WO-2016129983-A1 | NOVEL N-ACYL-ARYLSULFONAMIDE DERIVATIVES AS AMINOACYL-TRNA SYNTHETASE INHIBITORS | LATVIAN INSTITUTE OF ORGANIC SYNTHESIS (LV) | 2016-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022696-A1 | NOVEL N-ACYL-ARYLSULFONAMIDE DERIVATIVES AS AMINOACYL-TRNA SYNTHETASE INHIBITORS | AARS1, GARS1, ASNS | CA2 4520/4885CA9 4636/4885CA1 4860/4885 |
| US-11072581-B2 | N-acyl-arylsulfonamide derivatives as aminoacyl-tRNA synthetase inhibitors | AARS1, ASNS, GARS1 | CA2 4478/4885CA9 4589/4885CA1 4848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.